Patients with uveitis (n=10) | Patients without uveitis (n=7) | p Value | |
---|---|---|---|
Age (mean (SD)) | 38.1 (5.5) (n=10) | 40.6 (4.4) (n=7) | 0.34 |
Sex | |||
Males | 7 (70%) | 7 (100%) | 0.11 |
Females | 3 (30%) | 0 (0%) | |
Race | |||
Non-Hispanic white | 4 | 6 | 0.29 |
Non-Hispanic black | 4 | 1 | |
Hispanic | 1 | 0 | |
Other | 1 | 0 | |
Time from CMV retinitis diagnosis to start of cidofovir therapy (months) | 7.3 (5.5) (n=10) | 4.3 (6.0) (n=6) | 0.33 |
Previous anti-CMV retinitis therapy | |||
Ganciclovir | 1 | 1 | 0.68 |
Foscarnet | 1 | 0 | |
Ganciclovir and foscarnet | 7 | 5 | |
Duration of previous anti-CMV retinitis therapy (months) | 8.0 (5.6) (n=9) | 6.2 (6.3) (n=10) | 0.56 |
Medications used during cidofovir treatment | |||
Protease inhibitors | 7 (70%) | 6 (86%) | 0.45 |
Antiretrovirals | 9 (100%) | 5 (100%) | 1.0 |
HAART | 7 (70%) | 4 (80%) | 0.68 |
Rifabutin | 1 (10%) | 1 (14%) | 0.79 |
Sulpha antibiotics | 5 (56%) | 4 (80%) | 0.36 |
Fluconazole | 4 (44%) | 3 (60%) | 0.58 |
Diabetes mellitus | 0 (0%) | 1 (14%) | 0.22 |
Number of cidofovir doses | 8.0 (3.8) (n=10) | 6.9 (2.5) (n=7) | 0.47 |
CD4+ T lymphocyte count (×106/l) | 44.2 (75.3) (n=9) | 40.7 (54.0) (n=7) | 0.92 |
Duration between CD4+ T lymphocyte count measurement and cidofovir initiation (months) | 1.6 (1.4) (n=10) | 1.6 (1.6) (n=7) | 0.98 |
Serum creatinine (mg/dl) | 1.05 (0.29) (n=10) | 1.03 (0.32) (n=7) | 0.89 |
Proteinuria | |||
0+ | 5 | 3 | 0.77 |
Trace | 2 | 2 | |
1+ | 3 | 1 | |
2+ | 0 | 0 | |
3+ | 0 | 0 | |
4+ | 0 | 0 | |
Vision (logMAR units) | 0.121 (0.178) (n=9) | 0.164 (0.148) (n=7) | 0.62 |
Iris colour | |||
Blue | 2 | 2 | 0.25 |
Hazel | 1 | 3 | |
Brown | 6 | 2 | |
Intraocular pressure (mm Hg)∥ | 12.6 (1.7) (n=8) | 11.7 (4.3) (n=6) | 0.62 |
CMV retinitis | |||
Laterality | |||
Right eye | 2 | 2 | 0.68 |
Left eye | 5 | 2 | |
Both eyes | 3 | 3 | |
Extent of fundus involved | |||
<10% | 2 | 1 | 0.96 |
10–24% | 3 | 2 | |
25–49% | 2 | 2 | |
>50% | 2 | 1 | |
CMV retinitis in zone 1 | 6 (60%) | 5 (71%) | 0.63 |
↵p Value is comparison of therapy with foscarnet versus without foscarnet.
↵Highly active antiretroviral therapy (the combination of an HIV protease inhibitor with two or more nucleoside analogues).
↵Lesser of number of doses before uveitis or total number of doses.
↵Snellen visual acuity was recorded for the right eye in patients without uveitis or with bilateral uveitis, or the affected eye in patients with unilateral uveitis, and converted to logMAR units.11 12 ∥Intraocular pressure was recorded for the right eye in patients without uveitis or with bilateral uveitis, or the affected eye in patients with unilateral uveitis.
↵Lesions were assigned to the retinal zones described by Holland and associates.9